News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Drug Avastin Rejected by U.K. Agency National Institute for Clinical Excellence (NICE) for Use in Breast Cancer


12/8/2010 7:26:27 AM

Bloomberg -- Roche Holding AG’s Avastin failed to win the backing of the U.K. National Institute for Health and Clinical Excellence against breast cancer that has spread. The medicine’s “limited and uncertain benefit” when added to a type of chemotherapy called taxane is too small to justify the cost, the agency said today in an e-mailed statement. NICE advises the U.K.’s National Health Service on cost-effective treatments.

Read at Bloomberg
Read at Reuters
Read at Wall Street Journal
Read at Medical News Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES